Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,455 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bevacizumab with or after chemotherapy for platinum-resistant recurrent ovarian cancer: exploratory analyses of the AURELIA trial.
Bamias A, Gibbs E, Khoon Lee C, Davies L, Dimopoulos M, Zagouri F, Veillard AS, Kosse J, Santaballa A, Mirza MR, Tabaro G, Vergote I, Bloemendal H, Lykka M, Floquet A, Gebski V, Pujade-Lauraine E. Bamias A, et al. Among authors: dimopoulos m. Ann Oncol. 2017 Aug 1;28(8):1842-1848. doi: 10.1093/annonc/mdx228. Ann Oncol. 2017. PMID: 28481967 Free article. Clinical Trial.
Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study.
Kalofonos HP, Aravantinos G, Kosmidis P, Papakostas P, Economopoulos T, Dimopoulos M, Skarlos D, Bamias A, Pectasides D, Chalkidou S, Karina M, Koutras A, Samantas E, Bacoyiannis C, Samelis GF, Basdanis G, Kalfarentzos F, Fountzilas G. Kalofonos HP, et al. Among authors: dimopoulos m. Ann Oncol. 2005 Jun;16(6):869-77. doi: 10.1093/annonc/mdi193. Epub 2005 Apr 26. Ann Oncol. 2005. PMID: 15855226 Free article. Clinical Trial.
Association of ERCC1 SNPs with outcome in platinum-treated patients with advanced urothelial cancer: a Hellenic Cooperative Oncology Group study.
Nikitas N, Karadimou A, Tsitoura E, Soupos N, Tsiatas M, Karavasilis V, Pectasides D, Pavlidis N, Chrisofos M, Adamakis I, Murray S, Fountzilas G, Dimopoulos MA, Bamias A. Nikitas N, et al. Among authors: dimopoulos ma. Pharmacogenomics. 2012 Nov;13(14):1595-607. doi: 10.2217/pgs.12.162. Pharmacogenomics. 2012. PMID: 23148636
Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2) plus carboplatin (6 AUC) in advanced non-small-cell lung cancer (NSCLC): a multicenter randomized trial. Hellenic Cooperative Oncology Group (HeCOG).
Kosmidis P, Mylonakis N, Skarlos D, Samantas E, Dimopoulos M, Papadimitriou C, Kalophonos C, Pavlidis N, Nikolaidis C, Papaconstantinou C, Fountzilas G. Kosmidis P, et al. Among authors: dimopoulos m. Ann Oncol. 2000 Jul;11(7):799-805. doi: 10.1023/a:1008389402580. Ann Oncol. 2000. PMID: 10997806 Free article. Clinical Trial.
Treatment of non-small cell lung cancer with gefitinib ('Iressa', ZD1839): the Greek experience with a compassionate-use program.
Razis E, Skarlos D, Briasoulis E, Dimopoulos M, Fountzilas G, Lambropoulos S, Rigatos S, Kopterides P, Efstathiou H, Tzamakou E, Bakoyannis C, Pectasides D, Makatsoris T, Varthalitis G, Papadopoulos S, Kosmidis P. Razis E, et al. Among authors: dimopoulos m. Anticancer Drugs. 2005 Feb;16(2):191-8. doi: 10.1097/00001813-200502000-00011. Anticancer Drugs. 2005. PMID: 15655417
Precision medicine in gynecological cancer (Review).
Aravantinou-Fatorou A, Georgakopoulou VE, Dimopoulos MA, Liontos M. Aravantinou-Fatorou A, et al. Among authors: dimopoulos ma. Biomed Rep. 2025 Jan 8;22(3):43. doi: 10.3892/br.2025.1921. eCollection 2025 Mar. Biomed Rep. 2025. PMID: 39810899 Free PMC article. Review.
Evaluating Minimal Residual Disease Negativity as a Surrogate Endpoint for Treatment Efficacy in Multiple Myeloma: A Meta-Analysis of Randomized Controlled Trials.
Ntanasis-Stathopoulos I, Filippatos C, Ntanasis-Stathopoulos A, Malandrakis P, Kastritis E, Tsitsilonis OE, Dimopoulos MA, Terpos E, Gavriatopoulou M. Ntanasis-Stathopoulos I, et al. Among authors: dimopoulos ma. Am J Hematol. 2025 Jan 9. doi: 10.1002/ajh.27582. Online ahead of print. Am J Hematol. 2025. PMID: 39784302
Pomalidomide, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Survival and Subgroup Analyses From the OPTIMISMM Trial.
Richardson P, Beksaç M, Oriol A, Lindsay J, Schjesvold F, Galli M, Yağcı M, Larocca A, Weisel K, Yu X, Donahue C, Acosta J, Peluso T, Dimopoulos M. Richardson P, et al. Among authors: dimopoulos m. Eur J Haematol. 2025 Jan 8. doi: 10.1111/ejh.14365. Online ahead of print. Eur J Haematol. 2025. PMID: 39777934
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.
Dimopoulos MA, Voorhees PM, Schjesvold F, Cohen YC, Hungria V, Sandhu I, Lindsay J, Baker RI, Suzuki K, Kosugi H, Levin MD, Beksac M, Stockerl-Goldstein K, Oriol A, Mikala G, Garate G, Theunissen K, Spicka I, Mylin AK, Bringhen S, Uttervall K, Pula B, Medvedova E, Cowan AJ, Moreau P, Mateos MV, Goldschmidt H, Ahmadi T, Sha L, Cortoos A, Katz EG, Rousseau E, Li L, Dennis RM, Carson R, Rajkumar SV; AQUILA Investigators. Dimopoulos MA, et al. N Engl J Med. 2024 Dec 9. doi: 10.1056/NEJMoa2409029. Online ahead of print. N Engl J Med. 2024. PMID: 39652675
1,455 results